Structure of CHK1 10-pt. mutant complex with LRRK2 indazole inhibitor compound 6

Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors.

CHK1 checkpoint homolog,Cell cycle checkpoint kinase,Checkpoint kinase-1

PFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLF
MELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERL
LNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLH
KILVENPSARITIPDIKKDRWYNKPLKK

7% PEG 8000, 16% ethylene glycol, 0.1 M MES (pH 6.5), 5% 6-aminohexanoic acid

kinase, Parkinson's disease, LRRK2, TRANSFERASE

PFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLF
LEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERL
LNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLH
KILVENPSARITIPDIKKDRWYNKPLKK